Karyopharm Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview

Karyopharm Therapeutics

09/02/2024 14:17

* Karyopharm Therapeutics Inc  KPTI.OQ   KPTI.O  is expected
to show a rise in quarterly revenue when it reports  results on
February 13 (estimated) for the period ending December 31 2023
    * The Newton Center Massachusetts-based  company is expected
to
report a 5.3% increase in revenue to $35.348 million from $33.58
million a year ago, according to the mean estimate from 7
analysts, based on LSEG data.The company's guidance on January 8
2024, for the period ended December 31, was for revenue of
$33.600 million.
    * ​LSEG's mean analyst estimate for Karyopharm Therapeutics
Inc is
for a loss of 31 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Karyopharm
Therapeutics Inc is $5.00​, above​ its last closing price
of $1.51. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.28       -0.28      -0.30     Missed  -7.1
 Jun. 30 2023  -0.35       -0.34      -0.29     Beat    15.3
 Mar. 31 2023  -0.36       -0.37      -0.30     Beat    18.5​
 Dec. 31 2022  -0.35       -0.35      -0.43     Missed  -21.8
 ​​Sep.        -0.58       -0.57      -0.45     Beat    20.4
 30 2022                                                
 Jun. 30 2022  -0.63       -0.63      -0.62     Beat    2.1​
 Mar. 31 2022  -0.62       -0.63      -0.53     Beat    16
 Dec. 31 2021  -0.35       -0.52      0.46      Beat    189.2
 This summary was machine generated February 9 at 14:16 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)